论文部分内容阅读
目的：分析天普洛欣静脉溶栓治疗对急性心肌梗死（AMI）患者的疗效与安全性。方法：选择符合静脉溶栓标准的AMI192例患者给予静滴天普洛欣（尿激酶）150万u，并辅以阿斯匹林、肝素及常规治疗，观察冠脉再通及心脏事件发生率、5周死亡率及出血倾向。结果：①冠脉再通62例，其再通率67．4％；②发病至开始溶栓时间＜6h患者，冠脉再通率达81％，＞6h者仅50％（P＜0．005）；③冠脉再通患者的心脏事件发生率为30．65％，5周死亡率为4．84％，而未通患者分别为53．33％和20％（P＜0．025～0．05）；④出现出血倾向10例。结论：天普洛欣静脉溶栓治疗AMI有效且相对安全。
Objective: To analyze the efficacy and safety of the thrombolysis thrombolytic therapy in patients with acute myocardial infarction (AMI). Methods: One hundred and ninety-five thousand ug of intravenous thromboxane (urokinase) was given to 192 patients with AMI who were eligible for intravenous thrombolysis and supplemented with aspirin, heparin and routine treatment to observe the rate of coronary recanalization and cardiac events , 5-week mortality and bleeding tendency. Results: ①The recanalization of coronary artery was performed in 62 cases, with the recanalization rate of 67.4%. ② The incidence of recanalization of coronary artery was 81% and only 50% of those of> 6 h after onset of thrombolysis <6 h (P <0. 005). The incidence of cardiac events in patients with coronary recanalization was 30.65% and the 5-week mortality rate was 4.84%, while the number of failed patients was 53.33% and 20% respectively (P <0.025 ~ 0.05); ④ Bleeding tendency ten cases. Conclusion: The thrombolysis thrombolytic therapy of AMI is effective and relatively safe.